Company intelligence / Profile preview

TARGIT

Ownership: Private
Development stage: Other

Overview

Targit was a biotechnology company focused on the development of site-specific drug delivery systems, particularly for the gastrointestinal tract. The company's core asset was the TARGIT technology, a pH-sensitive coating system designed to release therapeutic agents specifically in the colon. This platform was intended to improve the treatment of localized conditions such as inflammatory bowel disease and colorectal cancer by increasing local drug concentration while minimizing systemic side effects. The technology was eventually acquired and integrated into the portfolio of West Pharmaceutical Services.

Therapeutic areas: OncologyGastroenterology
Modalities: Small moleculePeptidesProtein
Industry: Biotech

Partnerships

West Pharmaceutical Services

Beyond the preview

Go deeper on TARGIT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TARGIT.

Explore the full profile